enGene Therapeutics Inc.: EVENTIDE ASSET MANAGEMENT, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Eventide Asset Management disclosed a stake exceeding 5% in enGene Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0001580642-26-007717). The filing signals that Eventide has crossed the 5% beneficial ownership threshold, making it a reportable major holder in the clinical-stage gene therapy developer. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify the size and nature of Eventide's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
enGene Therapeutics Inc., Eventide Asset Management, LLC